Clinical Trials on Multiple Chronic Conditions

Total 434029 results

EMD Serono

Withdrawn

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

Relapsing-Remitting Multiple Sclerosis
Fundacion Clinica Valle del Lili
University of Pittsburgh; Hospital Universitario del Valle Evaristo Garcia

Recruiting

Whole Blood in Trauma Patients With Hemorrhagic Shock (WEBSTER)

Trauma | Trauma Injury | Trauma, Multiple

Colombia
Arizona State University

Recruiting

Brain Mechanisms of Reducing Polysubstance Use

Multiple Drug Use

United States
William Evans
Georgia Southern University; Health Association of Niagara County, Inc.; Catholic... and other collaborators

Recruiting

Evaluating the Impact of Senior Companion Programs

Aging | Disabilities Multiple

United States
Desitin Arzneimittel GmbH
BioPharma Services, Inc

Completed

Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets

Multiple Drug Use

Canada
Duke University

Completed

Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT

Multiple Myeloma | Chronic Lymphocytic Leukemia

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Novartis Pharmaceuticals

Completed

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (PASSOS)

Relapsing Remitting Multiple Sclerosis RRMS

Germany, Switzerland
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

Fatigue | Relapsing-Remitting Multiple Sclerosis

Sweden, Norway, Austria, Denmark
GE Healthcare
Centre for Probe Development and Commercialization

Completed

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Relapsing-remitting Multiple Sclerosis (rrMS)

Canada
Novartis Pharmaceuticals

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Relapsing-remitting Multiple Sclerosis | RRMS

Russian Federation, Ukraine, Czech Republic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM)

Chronyc Myeloid Leukemia

Netherlands, Italy
Hospices Civils de Lyon

Recruiting

Pediatric Immune Response to Multi-Organ Dysfunction (PedIMOD)

Multiple Organ Dysfunction Syndrome

France
Chinese PLA General Hospital

Unknown

The Prognostic Assessment of Extubation in Aged Patients With Multiple Organ Dysfunction Syndrome

Multiple Organ Dysfunction Syndrome

China
Hospital Universitario Principe de Asturias
Pfizer

Unknown

6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome (NAIF)

Multiple Organ Dysfunction Syndrome

Spain
UMC Utrecht

Terminated

The Role of Post-traumatic Inhibition of the Innate and Adaptive Immune System in the Development of Infectious Complications in Severely Injured Patients (POSEIDON)

Sepsis | Multiple Trauma | Innate Immune Response | Multiple Organ Dysfunction Syndrome | Disorder of Neutrophils

Netherlands
Universitätsklinikum Hamburg-Eppendorf
Neovii Biotech; Clinical Trial Center North (CTC North GmbH & Co. KG)

Terminated

Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial (COAST)

Relapsing-Remitting Multiple Sclerosis

Germany
Biogen

Terminated

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)

Relapsing-Remitting Multiple Sclerosis

Canada
Bayer

Completed

Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

Relapsing-remitting Multiple Sclerosis

France
Biogen

Completed

GER-009-06-AVX Early Therapy in Multiple Sclerosis (FIT)

Relapsing-Remitting Multiple Sclerosis
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
University of Washington
National Multiple Sclerosis Society

Active, not recruiting

MBCT and CBT for Chronic Pain in Multiple Sclerosis

Multiple Sclerosis

United States
US Department of Veterans Affairs

Completed

Cognitive-behavior Therapy for MS-Related Chronic Pain

Multiple Sclerosis

United States
University of Cologne

Unknown

Quantification of Drugs and Their Degradation Products

Sepsis | Obesity | Kidney Failure, Chronic | Pregnancy | Multiple Organ Failure | Breast Feeding, Exclusive | Liver Insufficiency

Germany
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Rennes University Hospital

Recruiting

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. (TRIO)

Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis

France
Judit Pich

Recruiting

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis (TolDecCOMBINEM)

Relapsing-Remitting Multiple Sclerosis

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Spain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Kessler Foundation

Active, not recruiting

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, Germany

Completed

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

Relapsing-Remitting Multiple Sclerosis

United Kingdom
Anokion SA

Active, not recruiting

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)

Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)

United States
Ohio State University
National Multiple Sclerosis Society

Completed

Behavior and Activity Monitoring in MS

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
Karolinska Institutet
Patient-Centered Outcomes Research Institute; Kaiser Foundation Research Institute

Active, not recruiting

COMparison Between All immunoTherapies for Multiple Sclerosis. (COMBAT-MS)

Relapsing-remitting Multiple Sclerosis

Sweden
Biocad

Completed

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Relapsing-remitting Multiple Sclerosis

United States, Germany
Charite University, Berlin, Germany
Dr. Carmen Infante-Duarte

Terminated

Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod

Relapsing-Remitting Multiple Sclerosis

Germany
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Relapsing-remitting Multiple Sclerosis

Germany
Biogen

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Korea, Republic of, Taiwan, Czechia, Japan, Poland

Clinical Trials on Multiple Chronic Conditions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations